Export expansion and improved margins underpin sustained performance SINGAPORE, March 23, 2026 (GLOBE NEWSWIRE) — HomesToLife Ltd (Nasdaq: HTLM) (“HomesToLife” or the “Company”), a Singapore-based home furniture company with sales across Asia-Pacific, Europe and North America, today announced its audited financial results for the fiscal year ended December 31, 2025 (“FY2025”). “We are pleased to deliver strong operational and financial results for the full year, underpinned by our diversified export model and disciplined capital management,” said Ms. Phua Mei Ming, Chief Executive Officer of HomesToLife. “As we move forward, we will continue to execute our expansion strategy, deepen our presence in key markets, and ensure that HomesToLife remains well positioned to capture new growth opportunities.”Key Financial Highlights    FY2024     FY2025     Chg...

TAKHMAO, Cambodia, March 23, 2026 (GLOBE NEWSWIRE) — Kandal M Venture Limited (Nasdaq: FMFC) (“Kandal” or the “Company”), a contract manufacturer of affordable luxury leather goods with manufacturing operations in Cambodia, today announced its financial results for its first half of fiscal year 2026 ended September 30, 2025. Recent DevelopmentsStrategic Expansion into the PhilippinesOn March 9, 2026, the Company announced a strategic investment to expand its manufacturing capabilities into the Philippines-its first major expansion outside Cambodia. Kandal entered into a definitive agreement to acquire 15% equity interest in Dumaine International Ltd for US$2.5 million in an all-cash transaction. This investment supports the Company’s long-term strategy to diversify geographically, broaden its customer base, and enhance operational...

VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex”, “we” or “us”) (TSX: CFF) today reported results for the fourth quarter and year ended December 31, 2025. EBITDA* from continuing operations was negative $12.6 million for the quarter and negative $27.5 million for the year, compared to EBITDA of negative $2.1 million in the fourth quarter of 2024 and negative $13.6 million for the year. Net loss was $35.7 million or negative $0.87 per share for the year versus net loss in the preceding year of $29.8 million or $0.73 per share.  Selected Financial Highlights The following table summarizes our selected financial information for the comparative periods. Unless otherwise noted, financial information reflects results of continuing operations from our Mackenzie sawmill (the “Mackenzie...

BEIJING, March 23, 2026 (GLOBE NEWSWIRE) — Cheer Holding, Inc. (NASDAQ: CHR) (“Cheer Holding” or the “Company”), a leading provider of advanced mobile internet infrastructure and platform services, today announced its financial results for the fiscal year ended December 31, 2025. The Company’s Annual Report on Form 20-F was filed with the U.S. Securities and Exchange Commission on March 20, 2026. Management Commentary “We are pleased to report another year of solid financial performance, driven by continued momentum across our CHEERS ecosystem,” said Mr. Bing Zhang, Chairman and Chief Executive Officer of Cheer Holding. “Revenue growth was supported by new customer contributions, while we continued to advance our strategic focus on artificial intelligence and have begun laying the groundwork...

XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Plan to present new preclinical data at AACR for potential first-in-class masked T cell engager program targeting CLDN18.2 Extended cash runway through the end of 2027 WALTHAM, Mass., March 23, 2026 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2025. “As we enter 2026, we are well-positioned...

Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery technology represents significant outcome for Arbutus and Genevant Two additional patients from Phase 2a clinical trials of imdusiran achieve functional cure Milestone payment received under Alnylam LNP license for product candidate to treat hepatocellular carcinoma (HCC) WARMINSTER, Pa., March 23, 2026 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported fourth quarter and year end 2025 financial results and provided a corporate update. “We delivered another strong quarter, maintaining a disciplined approach...

Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA® in 1L/2L+ R/M HNSCC on track for the second half of 2026 Announced appointment of Thomas Civik as Interim Chief Executive Officer Expected cash runway into the fourth quarter of 2026 BOSTON, March 23, 2026 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat...

Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of 2026 Cash, cash equivalents and short-term investments of approximately $98 million as of December 31, 2025 expected to provide runway into 2028WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and year-end financial results for 2025. “2025 was a year of disciplined execution focused on the LOTUS trial, and we are thrilled to be approaching a transformational milestone with our topline data release expected in the second quarter of 2026,” said Dr. Garry Neil, Chief Executive...

All amounts in U.S. dollars unless otherwise stated TORONTO, March 23, 2026 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today released Convex Group Limited’s (“Convex”) audited financial results for the fourth quarter and full year 2025. This Supplemental Information Package follows the summary financial information released with Onex’ results on February 20 and is available on Onex’ website at https://www.onex.com/convex. Convex delivered strong performance in 2025, with Gross Premium Written and Net Premium Earned increasing by 14% and 20%, respectively, year-over-year. Underwriting results remained robust with a combined ratio of 89% and benefited from continued improvement in the expense ratio as Convex scales and captures operating leverage. Net income increased 40% to $711 million in 2025, up from $506 million in 20241. Onex...

WeRide Inc. Announces Fourth Quarter and Full Year 2025 Unaudited Financial Results NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) — WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD; HKEX: 0800), a global leader in autonomous driving technology, today announced its unaudited financial results for the fourth quarter and full year 2025 ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsTotal revenue was RMB314.0 million (US$44.9 million), representing an increase of 123.0% year over year.Product revenue was RMB211.4 million (US$30.2 million), representing an increase of 308.9% year over year, primarily attributable to increased revenue from robotaxi and robobus sales. Service revenue was RMB102.6 million (US$14.7 million), representing an increase of 15.2% year over year. Robotaxi revenue was RMB50.6 million (US$7.2...